Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Dionne (2011)
The Role of Executive Time Horizons in State Response to AIDS in AfricaComparative Political Studies, 44
S. Geiger, A. McMahon (2021)
Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID?19: too many cooks or too many recipes?
X. Dai (2007)
International institutions and national policies
(2021a)
COVAX global supply forecast
P. Hall (1993)
Policy paradigms, social learning, and the state: the case of economic policymaking in BritainComparative politics, 25
(2020d)
Operationalising the COVID?19 technology access Pool (C?TAP)
C.M. Correa (2021)
Expanding the production of COVID?19 vaccines to reach developing countries. Lift the barriers to fight the pandemic in the global south
(2020b)
Fair allocation mechanism for COVID?19 vaccines through the COVAX facility
(2022)
External evaluation of the external evaluation of the access to COVID?19 access to COVID?19 tools tools accelerator (ACT?A) accelerator (ACT?A)
D. McAdams, K. McDade, O. Ogbuoji, M. Johnson, S. Dixit, G. Yamey (2020)
?Incentivising wealthy nations to participate in the COVID?19 vaccine global access facility (COVAX): a game theory perspective?, BMJ, 5
(2020)
Extroaordinary G20 Leaders' summit: statement on COVID?19
Siddhanth Sharma, Nisrine Kawa, A. Gomber (2021)
WHO’s allocation framework for COVAX: is it fair?Journal of Medical Ethics
S. Moon, J. Armstrong, B. Hutler, R. Upshur, R Katz, C. Atuire (2021)
Governing the access to COVID?19 tools accelerator: towards greater participation, transparency, and accountability, 399
Frederick Abbott, J. Reichman (2020)
Facilitating Access to Cross-Border Supplies of Patented Pharmaceuticals: The Case of the COVID-19 PandemicJournal of International Economic Law
Carla Norrlöf (2020)
Is COVID-19 the end of US hegemony? Public bads, leadership failures and monetary hegemonyInternational Affairs, 96
I. Kaul (2016)
Global Public Goods
(2021)
Unequal, unprepared, under threat
M.M. Kavanagh, I.T. Katz, C.B. Holmes (2020)
Reckoning with mortality: global health, HIV, and the politics of data, 396
W. Byanyima (2022)
HIV or COVID?19, inequity is deadly, 6
(2020)
Waiver from certain provisions of the TRIPS agreement for the prevention, containment and treatment of COVID?19. IP/C/W/669
M.R.Q. Davies (2022)
Covid-19: WHO efforts to bring vaccine manufacturing to Africa are undermined by the drug industry, documents showBMJ, 376
M. Finnemore, Kathryn Sikkink (1998)
International Norm Dynamics and Political ChangeInternational Organization, 52
(2021c)
One world protected: the Gavi COVAX AMC investment opportunity
M. Eccleston‐Turner, H. Upton (2021)
International collaboration to ensure equitable access to vaccines for COVID?19: the ACT?accelerator and the COVAX facility, 99
S. Thambisetty (2021)
The TRIPS Intellectual Property Waiver Proposal: Creating the Right Incentives in Patent Law and Politics to end the COVID-19 PandemicSocial Science Research Network
D. Collier (2011)
Understanding process tracing, 44
S.N. Uwaezuoke (2020)
Strengthening health systems in Africa: the COVID?19 pandemic fallout, 1
K. Kupferschmidt (2020)
‘Vaccine nationalism’ threatens global plan to distribute COVID-19 shots fairlyScience
S. Fukuda‐Parr, D. Hulme (2011)
International norm dynamics and the "end of poverty": Understanding the millennium development goalsGlobal Governance, 17
Kenneth Abbott, D. Snidal (2000)
Hard and Soft Law in International GovernanceInternational Organization, 54
B. Simmons (1998)
COMPLIANCE WITH INTERNATIONAL AGREEMENTSAnnual Review of Political Science, 1
S.L. Smith, J. Shiffman, Y.R. Shawar, Z.C. Shroff (2021)
The rise and fall of global health issues: an arenas model applied to the COVID?19 pandemic shock, 17
M.Z. Abbas (2020)
Practical implications of ?vaccine nationalism?: a short?sighted and risky approach in response to COVID?19. 124
O. Aginam (2014)
Law and Global Health
T.A. Ghebreyesus (2022)
WHO director?General's opening remarks at the WHO press conference ? 30 march 2022
I. Kaul, I. Grunberg, M. Stern (1999)
Global public goods: international cooperation in the 21st century
S.E. Davies, A. Kamradt‐Scott, S. Rushton (2015)
Disease diplomacy: international norms and global health security
Abbas M.Z. (2020)
34
Giulietta Maruggi, Cuiling Zhang, Junwei Li, J. Ulmer, Dong Yu (2019)
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.Molecular therapy : the journal of the American Society of Gene Therapy, 27 4
K. Kieslich (2018)
Addressing vaccination hesitancy in Europe: a case study in state–society relationsThe European Journal of Public Health, 28
J. Shiffman, S. Smith (2007)
Generation of political priority for global health initiatives: a framework and case study of maternal mortality, 370
M. Kavanagh, Lawrence Gostin, M. Sunder (2021)
Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic.JAMA
S. Sekalala (2017)
Soft law and global health problems : lessons from responses to HIV/AIDS, malaria and tuberculosis
(2020a)
COVID?19 response
R.D. Putnam (1988)
Diplomacy and domestic politics: the logic of two?level games, 42
A.D. Usher (2021)
A beautiful idea: how COVAX has fallen short, 397
(2020a)
COVAX explained
J.S. Solís Arce, S.S. Warren, N.F. Meriggi, A. Scacco, N. McMurry, M. Voors (2021)
COVID?19 vaccine acceptance and hesitancy in low? and middle?income countries, 27
M. Cueto (2004)
The ORIGINS of primary health care and SELECTIVE primary health care, 94
A. Bengy Puyvallée, K.T. Storeng (2022)
COVAX, vaccine donations and the politics of global vaccine inequity, 18
L.J. Abu‐Raddad, H. Chemaitelly, A.A. Butt (2021)
Effectiveness of the BNT162b2 Covid?19 vaccine against the B.1.1.7 and B.1.351 variants, 385
Leroy Versteeg, Mashal Almutairi, P. Hotez, J. Pollet (2019)
Enlisting the mRNA Vaccine Platform to Combat Parasitic InfectionsVaccines, 7
C. Bradley, J. Kelley (2006)
The Concept of International DelegationLaw and contemporary problems, 71
(2020)
The tragedy of vaccine nationalism: only cooperation can end the pandemic
S. Davies, C. Wenham (2020)
Why the COVID-19 response needs International RelationsInternational Affairs, 96
S. Moore, E.M. Hill, L. Dyson, M.J. Tildesley, M.J. Keeling (2022)
Retrospectively modeling the effects of increased global vaccine sharing on the COVID?19 pandemic, 28
O.J. Watson, G. Barnsley, J. Toor, A.B. Hogan, P. Winskill, A.C. Ghani (2022)
Global impact of the first year of COVID?19 vaccination: a mathematical modelling study, 22
J. Nkengasong, N. Ndembi, Akhona Tshangela, T. Raji (2020)
COVID-19 vaccines: how to ensure Africa has accessNature, 586
C.D.C. Africa (2020)
Framework for fair, equitable and timely allocation of COVID?19 vaccines in Africa
(2020)
COVAX facility explainer: participation arrangements for self?financing economies
Y. Ye, Q. Zhang, X. Wei, Z. Cao, H.Y. Yuan, D.D. Zeng (2022)
Equitable access to COVID?19 vaccines makes a life?saving difference to all countries, 6
Ş.İ. Özler (2020)
The United Nations at seventy?five: passing the COVID test?, 34
E. Kapstein, J. Busby (2013)
AIDS drugs for all: social movements and market transformations
International mechanisms failed to achieve equitable distribution of COVID‐19 vaccines—prolonging and deepening the pandemic. To understand why, we conduct process tracing of the first year of international policymaking on vaccine equity. We find that, in the absence of a single venue for global negotiation, two competing law and policy paradigms emerged. One focused on demand and voluntary action by states and firms, while the alternative focused on opening knowledge and expanding production through national and international law. While these could have been complementary, power inequalities between key actors kept the second paradigm from gaining traction on the global agenda. The failure of the prevailing policy paradigm to secure equity is explained, not by unforeseen technical and financing challenges as some suggest, but by a fundamental misalignment with the political environment. While norm entrepreneurs encouraged sharing, political incentives pushed governments towards securing and hoarding doses. Firms responded to the latter. Mechanisms like COVAX proved incapable of countering these predictable international and domestic political forces. Earlier funding would not likely have changed the behaviour of states or firms in the absence of legal commitment. Barring significant geopolitical changes, a shift to include open/supply‐focused policies will be necessary to achieve equity in future pandemics.
Global Policy – Wiley
Published: May 1, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.